Company Search:
Advanced Search
Sponsored Links
Nicox SA Company Snapshot
Nicox SA operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Nicox SA with three other pharmaceutical manufacturers in Europe: Camurus AB of Sweden (2018 sales of 49.32 million Swedish Kronor [US$5.33 million] ), Premier Veterinary Group PLC of the United Kingdom (£3.15 million [US$4.07 million] of which 63% was PPCP UK), and Collagen Solutions PLC which is also based in the United Kingdom (£3.50 million [US$4.53 million] ).

Sales Analysis. During the year ended December of 2018, sales at Nicox SA were 4.00 million Euro (US$4.52 million). This is an increase of 73.5% versus 2017, when the company's sales were 2.31 million Euro.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Nicox SA
  Stock Performance Chart for Nicox SA
  Stock Data: Recent Stock Performance:
  Current Price (2/15/2019): 5.80
(Figures in Euro)
1 Week 1.1%   13 Weeks -6.8%  
4 Weeks 17.6%   52 Weeks -36.5%  
Nicox SA Key Data:
  Ticker: COX Country: France
  Exchanges: PAR Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2018 Sales 4,000,000
(Year Ending Jan 2019).
Employees: 28
  Currency: Euro Market Cap: 171,259,633
  Fiscal Yr Ends: December Shares Outstanding: 29,527,523
  Share Type: Actions Ordinaires Closely Held Shares: 2,094,747
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.